Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
What the Phase 2 Trial Data Shows According to data reviewed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), understanding clinical trial parameters is essential when setting expectations for any weight management medication
Human clinical trial data remains limited, with Phase I and II trials for inflammatory bowel disease conducted in the 1990s claiming safety with no toxicity, though full peer-reviewed data never appeared in scientific literature
When to stay at a dose longer than 4 weeks: You're still losing 1 to 2 pounds per week at the current dose You experienced moderate to severe nausea, vomiting, or diarrhea in the first 2 weeks of the current dose Your provider recommends a slower titration due to age, renal function, or other medications When to increase on schedule: Weight loss has slowed to less than 0.5 pounds per week for 2 consecutive weeks You tolerated the current dose with minimal side effects Your fasting glucose (if diabetic) or HbA1c has plateaued above target When NOT to increase: You're experiencing persistent nausea, vomiting more than twice per week, or signs of dehydration You've had an episode of pancreatitis (current or past) You're planning surgery or a medical procedure in the next 4 weeks (GLP-1 agonists delay gastric emptying, which affects anesthesia risk) The maximum FDA-studied dose is 15 mg weekly
Integrating the scoping review with insights derived from the NGT facilitates gathering real-world clinical insights
